Top

International Journal of Clinical Oncology

Published in:

01-12-2018 | Original Article

Prognostic and predictive value of plasma d-dimer levels in patients with small-cell lung cancer

Authors: Cuicui Zhang, Yongsheng Jia, Yanan Jia, Xiaoling Zhang, Kai Li

Published in: International Journal of Clinical Oncology | Issue 6/2018

Abstract

Background

To investigate the predictive value of plasma d-dimer levels for short-term therapeutic effect and progression-free survival (PFS) in patients with small-cell lung cancer (SCLC); and to analyze the correlation between baseline plasma d-dimer levels and other clinicopathological features. The aim of the study was to investigate whether the levels of plasma d-dimer could serve as a predictive and prognostic factor in patients with SCLC.

Methods

A retrospective review of the clinicopathological data of 160 patients with pathologically confirmed SCLC, who were treated at the Department of Thoracic Oncology of Tianjin Medical University Tumor Institute and Hospital between June 2011 and June 2016, was performed. At the same time, we collected 100 patients with benign pulmonary diseases as a control group. The correlations between baseline plasma d-dimer levels and other clinical features, therapeutic effect and PFS were analyzed statistically.

Results

The level of plasma d-dimer in patients with SCLC was significantly higher than that of patients with benign pulmonary diseases (P = 0.001). The PFS of patients with elevated d-dimer levels before therapy were significantly shorter than that of patients with normal d-dimer levels (6.0 versus 7.5 months, P = 0.013). The patients whose plasma d-dimer level always (before and after treatment) in the normal range have the best prognosis, and continuously elevated d-dimer carried out a poor prognosis (8.0 versus 5.0 months). According to multivariate analysis, elevated d-dimer level was confirmed to be an independent prognostic factor for worse survival (P = 0.029). The level of d-dimer was associated with tumor stage, the level of neuron-specific enolase, the presence of distant metastasis, hyponatremia, and the Karnofsky performance status score; and levels decreased when therapy was effective, but increased when the disease progressed.

Conclusions

High levels of baseline plasma d-dimer may indicate advanced disease stage and poor prognosis. Therefore, plasma d-dimer levels could serve as a predictive and prognostic factor in patients with SCLC.

Poleri C, Morero JL, Nieva B et al (2003) Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma. Histopathol Immunohistochem Anal Chest 123(6):1858–1867

Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRef

Govindan R, Page N, Morgensztern D et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539–4544CrossRef

Kuderer NM, Ortel TL, Francis CW (2009) Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27(29):4902–4911CrossRef

Altiay G, Ciftci A, Demir M et al (2007) High plasma d-dimer level is associated with decreased survival in patients with lung cancer. Clin Oncol 19:494–498CrossRef

Zhang P-P, Sun J-W, Wang X-Y et al (2013) Preoperative plasma d-dimer levels predict survival in patients with operable non-small cell lung cancer independently of venous thromboembolism. EJSO 39:951–956CrossRef

Chen Y, Yu H, Wu C et al (2016) Prognostic value of plasma d-dimer levels in patients with small-cell lung cancer. Biomed Pharmacother 81:210–217CrossRef

Antoniou D, Pavlakou G, Stathopoulos GP et al (2006) Predictive value of d-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer 53:205–210CrossRef

Zhou YX, Yang Z-M, Feng J et al (2013) High plasma d-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis. Tumor Biol 34:3701–3704CrossRef

10.

Ge L-P, Li J, Bao Q-L et al (2015) Prognostic and predictive value of plasma d-dimer in advanced non-small cell lung cancer patients undergoing first-line chemotherapy. Clin Transl Oncol 17:57–64CrossRef

11.

Jiang H-G, Li J, Shi S-B et al (2014) Value of fibrinogen and d-dimer in predicting recurrence and metastasis after radical surgery for non-small cell lung cancer. Med Oncol 31:22CrossRef

12.

Chen X, Fang J, Nie J et al (2014) Multivariate analysis of prognostic factors in the eldly patients with small cell lung cancer: a study of 160 patients. Chin J Lung Cancer 17(1):15–23

13.

Bremnes RM, Sundstrom S, Aasebø U et al (2003) The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39(3):303–313CrossRef

14.

Shibayama T, Ueoka H, Nishii K et al (2001) Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung cancer 32: 61–69CrossRef

15.

Zhang Y, He Q, Yang H et al (2015) Correlative study on plasma levels of fibrinogen, d-dimer, platelet count and short-term effect in patients with extensive stage small lung cancer. J Gannan Med Univ 35(3):379–382

16.

John A (2005) Cancer and venous thromboembolism: scope of the problem. Cancer Control 12(1):5–11CrossRef

17.

Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745–749CrossRef

18.

Gil-Bernabė AM, Ferjančič Š, Tlalka M et al (2012) Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 119(13):3164–3175CrossRef

19.

Rijken DC, Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7:4–13CrossRef

20.

Bikdeli B, Sharif-Kashani B, Chitsaz E et al (2011) Dexter versus sinister deep vein thrombosis: which is the more sinister? Findings from the NRITLD DVT registry. Sem Thromb Hemost 37(3):298–304CrossRef

21.

Zhang P, Sun J, Lu J et al (2013) Correlation between baseline plasma d-dlnler levels and prognosis in patients wltb non-sInal cell lung cancer. Chin J Oncol 35(10):747–750

22.

Gieseler F, Lühr I, Kunze T et al (2007) Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. Thromb Haemost 97:1023–1030CrossRef

Title: Prognostic and predictive value of plasma d-dimer levels in patients with small-cell lung cancer
Authors: Cuicui Zhang
Yongsheng Jia
Yanan Jia
Xiaoling Zhang
Kai Li
Publication date: 01-12-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1320-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Cardiac output response to exercise in patients before allogenic hematopoietic stem cell transplantation

Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction

Comparison of the University of Pittsburgh staging system and the eighth edition of the American Joint Committee on Cancer TNM classification for the prognostic evaluation of external auditory canal cancer

Secondary cancer after a childhood cancer diagnosis: viewpoints considering primary cancer

Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy

Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer